巴瑞替尼对活动性类风湿关节炎患者血脂、载脂蛋白及脂蛋白颗粒谱的影响:IIb期研究
该IIb期随机对照研究纳入301例中重度活动性类风湿关节炎患者,评估巴瑞替尼(1、2、4、8 mg每日一次)或安慰剂对血脂谱及脂蛋白颗粒的影响。结果显示巴瑞替尼导致剂量依赖性血脂升高,但HDL胆固醇升高与疾病活动度改善相关,且大LDL颗粒增加、小而密LDL颗粒减少,HDL相关血清淀粉样A降低。
要点
- 巴瑞替尼治疗12周出现剂量依赖性血脂升高,LDL-C、HDL-C和甘油三酯均升高,但HDL-C升高与疾病活动度改善相关。
- 巴瑞替尼增加大LDL颗粒、减少小而密LDL颗粒,并降低HDL相关血清淀粉样A,8 mg剂量还降低脂蛋白(a)。
- 载脂蛋白A-I、B和CIII升高,但LDL相关载脂蛋白CIII未升高,提示血脂变化模式可能与心血管风险关联复杂。
核心结论
- 巴瑞替尼治疗活动性类风湿关节炎引起剂量依赖性血脂升高,但HDL胆固醇升高与临床疗效改善相关,且脂蛋白颗粒谱变化提示心血管风险影响需进一步评估。
研究设计与样本
- IIb期随机对照研究,纳入301例中重度活动性类风湿关节炎患者,随机接受巴瑞替尼1、2、4、8 mg每日一次或安慰剂治疗。
主要发现
- 从基线至第12周,LDL胆固醇在1 mg和8 mg组分别升高3.4 mg/dl和11.8 mg/dl,HDL胆固醇分别升高3.3 mg/dl和8.1 mg/dl,甘油三酯分别升高6.4 mg/dl和15.4 mg/dl。
- LDL胆固醇平均升高与大LDL颗粒平均增加及小而密LDL颗粒平均减少同时发生。
- 第12周HDL胆固醇升高与疾病活动度评分和简化疾病活动指数改善相关;总胆固醇、LDL胆固醇和甘油三酯变化未显示类似关系。
- 第4周和第12周,4 mg和8 mg巴瑞替尼组载脂蛋白A-I分别升高9.5%和12.2%,载脂蛋白B分别升高6.8%和7.1%,载脂蛋白CIII分别升高23.0%和19.7%。
- 4 mg和8 mg巴瑞替尼组LDL相关载脂蛋白CIII分别变化-4.5%和-9.0%,HDL相关血清淀粉样A分别降低36.0%和32.0%,8 mg组脂蛋白(a)降低16.6%。
临床怎么用
- 使用巴瑞替尼治疗活动性类风湿关节炎时,应监测血脂变化,但HDL胆固醇升高可能与临床疗效改善相关,需综合评估心血管风险。
局限性
- 本研究为IIb期研究,样本量有限,血脂和脂蛋白颗粒变化的长期心血管影响未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effects of baricitinib on lipid profiles in patients with moderate-to-severe rheumatoid arthritis. METHODS: Treatment with once-daily doses of baricitinib (1, 2, 4, or 8 mg) or placebo was studied in 301 randomized patients. Changes in lipid profile and lipoprotein particle size and particle number were assessed at weeks 12 and 24, and associations with clinical efficacy were evaluated. Apolipoproteins were assessed at weeks 4 and 12 in the placebo group and the 4-mg and 8-mg baricitinib groups. RESULTS: Treatment with baricitinib resulted in dose-dependent increases in serum lipid levels from baseline to week 12 (low-density lipoprotein [LDL] cholesterol increases of 3.4 mg/dl and 11.8 mg/dl in the 1 mg and 8 mg treatment groups, respectively; high-density lipoprotein [HDL] cholesterol increases of 3.3 mg/dl and 8.1 mg/dl, respectively; triglycerides increases of 6.4 mg/dl and 15.4 mg/dl, respectively). Group-wise mean increases in LDL cholesterol were coincident with mean increases in large LDL particles and mean reductions in small dense LDL particles. Increases from baseline to week 12 in apolipoprotein A-I, apolipoprotein B, and apolipoprotein CIII were observed with 4-mg doses of baricitinib (9.5%, 6.8%, and 23.0%, respectively) and with 8-mg doses (12.2%, 7.1%, and 19.7%, respectively), with no increase in LDL-associated apolipoprotein CIII (-4.5% with 4-mg baricitinib; -9.0% with 8-mg baricitinib). Baricitinib reduced HDL-associated serum amyloid A when administered at 4 mg (-36.0%) and 8 mg (-32.0%); a significant reduction in lipoprotein (a) was observed only with 8-mg doses (-16.6%). Increased HDL cholesterol at week 12 correlated with improved Disease Activity Scores and Simplified Disease Activity Index; changes in total cholesterol, LDL cholesterol, and triglycerides did not reveal a similar relationship. CONCLUSION: Baricitinib-associated increases in serum lipid levels were observed in this study. Increases in levels of HDL cholesterol correlated with improved clinical outcomes.
引用
- Kremer JM, Genovese MC, Keystone E, et al. Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis Rheumatol. 2017. PMID: 28029752. doi:10.1002/art.40036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。